Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CDx

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: CDx. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000091-11 Sponsor Protocol Number: PR200-102 Start Date*: 2021-09-21
    Sponsor Name:Prometheus Biosciences, Inc.
    Full Title: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Activ...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000248-23 Sponsor Protocol Number: C3441052 Start Date*: 2021-10-22
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
    Medical condition: Metastatic Castration-sensitive Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002409-23 Sponsor Protocol Number: CLN-081-001(REZILIENT1) Start Date*: 2020-02-27
    Sponsor Name:Cullinan Oncology Inc.
    Full Title: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small C...
    Medical condition: Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003248-63 Sponsor Protocol Number: QBGJ398-302 Start Date*: 2020-02-19
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alt...
    Medical condition: Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10046731 Urothelial carcinoma urethra recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Prematurely Ended) BG (Prematurely Ended) PT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001957-29 Sponsor Protocol Number: Brigatinib-3001 Start Date*: 2018-12-13
    Sponsor Name:ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.)
    Full Title: A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progresse...
    Medical condition: ALK positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) GR (Prematurely Ended) HR (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-001596-14 Sponsor Protocol Number: TYR300-101 Start Date*: 2023-06-26
    Sponsor Name:Tyra Biosciences, Inc.
    Full Title: A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF 301)
    Medical condition: Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004207-39 Sponsor Protocol Number: AGO-OVAR2.34 Start Date*: 2021-06-07
    Sponsor Name:AGO Research GmbH
    Full Title: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC ...
    Medical condition: This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-ba...
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004773-29 Sponsor Protocol Number: GO41854 Start Date*: 2020-08-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT...
    Medical condition: Non−small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002925-31 Sponsor Protocol Number: GO41717 Start Date*: 2020-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN ...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Prematurely Ended) PL (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005562-39 Sponsor Protocol Number: P060205 Start Date*: 2008-08-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: ALFA 0703 : A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Chemotherapy or azacitidine as salvage therapy and Azacitidine as Mai...
    Medical condition: Older patients with acute myeloblastic leukemia (AML).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000878 LAM PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000040-26 Sponsor Protocol Number: CA209-8HW Start Date*: 2019-07-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-...
    Medical condition: Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) IE (Completed) FR (Trial now transitioned) DK (Trial now transitioned) ES (Restarted) CZ (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001966-39 Sponsor Protocol Number: CBYL719C2303 Start Date*: 2021-09-27
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advan...
    Medical condition: Hormone receptor positive, HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003509-80 Sponsor Protocol Number: IMGN853-0416 Start Date*: 2020-09-07
    Sponsor Name:ImmunoGen, Inc.
    Full Title: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Periton...
    Medical condition: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Completed) PL (Completed) PT (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002605-10 Sponsor Protocol Number: CJDQ443B12301 Start Date*: 2022-04-01
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic K...
    Medical condition: Advanced non-small cell lung cancer harboring the KRAS G12C mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Trial now transitioned) ES (Ongoing) NO (Completed) GR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) DK (Completed) SI (Trial now transitioned) EE (Completed) IT (Trial now transitioned) PL (Completed) HR (Completed) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003315-35 Sponsor Protocol Number: B7461006 Start Date*: 2017-08-01
    Sponsor Name:Pfizer Inc,
    Full Title: A Phase 3, randomized, open-label study of lorlatinib (PF-06463922) monotherapy versus crizotinib monotherapy in the first-line treatment of patients with advanced ALK-positive non-small cell lung ...
    Medical condition: Advanced ALK positive non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) CZ (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002695-40 Sponsor Protocol Number: MO43156 Start Date*: 2021-12-28
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIAT...
    Medical condition: Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001833-14 Sponsor Protocol Number: EAURF2018-02 Start Date*: 2020-12-04
    Sponsor Name:EAU Research Foundation
    Full Title: Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who hav...
    Medical condition: pT3-4 and/or pN1-3 urothelial carcinoma (UC) of the urinary bladder or upper urinary tract after radical cystectomy /radical nephroureterectomy previously treated with at least three cycles of ne...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001548-36 Sponsor Protocol Number: CO40016 Start Date*: 2017-12-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATI...
    Medical condition: Locally advanced unresectable or metastatic triple-negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer or locally advanced unresectable or metastatic hormone recept...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BE (Completed) FR (Completed) GR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004161-13 Sponsor Protocol Number: ZN-c3-006 Start Date*: 2022-04-24
    Sponsor Name:K-Group Beta, Inc.
    Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
    Medical condition: Platinum-resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:02:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA